English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

In the last 3 years, clinical and pre-clinical studies demonstrated a progressive increase in the concentration of Gadolinium in the brain of patients with normal renal function, following repeated injections of some of the commercially approved Gadolinium Based Contrast Agents (GBCA). Till now no association has been demonstrated between Gadolinium presence in the brain and any kind of neurological signs or symptoms, but there’s need to modify the current approach in using Gadolinium contrast media in daily clinical practice, in order to reduce unknown possible risks for patients. On 21 July 2017, the European Medicines Agency (EMA) confirmed the suspension of the authorisations for the European market for four GBCAs, due to Gadolinium deposition in brain tissue. Recently, some recommendations are produced on behalf of the International Society for Magnetic Resonance in Medicine, an attempt to balance the potential harm of Gadolinium deposition with the proven clinical utility of GBCA.

Gadolinium Retention in the Human Body after Administration of Magnetic Resonance Contrast Agents: Where We are Now